ERBB2 and cancer: Trastuzumab and pertuzumab are monoclonal antibodiesfor the treatmentof patients with human epidermal growth factor receptor-2 (HER2) positivebreast cancer with an increase in overall survival upon treatment.30−32 Mass spectrometry is a key method for the structural characterizationof monoclonal antibodies to analyze structural integrity and post-translationalmodifications.